4564.T Stock Drops 7.4% on April 23 as OncoTherapy Science Faces Headwinds

OncoTherapy Science, Inc. (4564.T) traded lower on the JPX today, with 4564.T stock declining 7.4% to close at ¥25.0 on April 23, 2026. The Japanese biotech company, headquartered in Kawasaki, develops anti-cancer medicines and therapies including small-molecule drugs and cancer-specific peptide vaccines. Trading volume surged to 173.2 million shares, well above the average of 77.4 million, signaling heavy selling pressure. The stock has retreated from its 52-week high of ¥35.0, now trading near mid-range levels. Meyka AI’s analysis reveals significant headwinds facing this clinical-stage biotech firm.

Market Performance and Trading Activity

OncoTherapy Science’s 4564.T stock opened at ¥27.0 before sliding to a low of ¥25.0, marking a ¥2.0 decline from the previous close. The intraday range spanned from ¥25.0 to ¥28.0, reflecting volatile sentiment among investors. Trading volume reached 173.2 million shares, representing 224% of average daily volume, indicating substantial institutional and retail selling.

The stock’s five-day performance shows weakness, with a 7.14% decline over the past week. However, year-to-date performance remains positive at 23.8%, suggesting earlier momentum has faded. The market cap stands at approximately ¥893.5 billion, with 343.6 million shares outstanding. Track 4564.T on Meyka for real-time updates on this volatile biotech name.

Financial Metrics and Valuation Concerns

4564.T stock faces significant valuation challenges that explain today’s selloff. The company trades at a price-to-sales ratio of 11.83x, substantially above sector averages, while carrying a negative earnings per share of -¥2.83. The price-to-book ratio of 4.55x suggests the market prices in future growth that remains unproven.

Key financial metrics reveal operational stress. Return on equity stands at -63%, while return on assets sits at -35.5%, indicating losses on shareholder capital. The company maintains a strong cash position of ¥6.06 per share, providing runway for clinical development. However, with 65.8% of revenue dedicated to R&D expenses, profitability remains distant. Gross margins are razor-thin at just 3.6%, reflecting the early-stage nature of biotech operations.

Clinical Pipeline and Development Status

OncoTherapy Science’s pipeline includes multiple candidates at various clinical stages. OTS167, a maternal embryonic leucine zipper kinase inhibitor, is in Phase I/II trials for acute myeloid leukemia and Phase I for breast cancer. S-588410, a cancer-specific peptide vaccine, has advanced to Phase III trials for esophageal cancer and Phase II for bladder cancer.

The company also develops OTS964 for various cancer diseases and OTSA101 for synovial sarcoma in Phase I trials. Additionally, KHK6640, an anti-amyloid beta peptide antibody, is being tested for Alzheimer’s disease. With earnings announcement scheduled for May 11, 2026, investors await updates on trial progress and cash burn rates. The diversified pipeline offers multiple shots on goal, though clinical success remains uncertain.

Market Sentiment and Technical Outlook

Technical indicators suggest mixed signals for 4564.T stock. The RSI of 53.36 indicates neutral momentum, neither overbought nor oversold. The ADX of 42.28 confirms a strong downtrend is in place, warning of continued selling pressure. The MACD histogram of 0.19 shows weakening momentum, with the signal line above the MACD line.

Bollinger Bands position the stock near the middle band at ¥24.80, with support at ¥19.30 and resistance at ¥30.30. The Money Flow Index of 60.50 suggests institutional accumulation despite price weakness, potentially indicating a bottom-fishing opportunity. However, Meyka AI rates 4564.T stock with a C- grade and strong sell recommendation, factoring in sector performance, financial metrics, and analyst consensus. This grade reflects significant fundamental challenges ahead.

Final Thoughts

OncoTherapy Science (4564.T) faces a challenging environment as 4564.T stock declined sharply on April 23, 2026. The biotech company’s weak profitability metrics, high valuation multiples, and negative earnings per share justify today’s selloff. While the clinical pipeline offers long-term potential with multiple cancer and Alzheimer’s candidates in development, near-term catalysts remain limited. The strong trading volume suggests institutional repositioning rather than panic selling. Investors should monitor the May 11 earnings announcement for cash burn updates and trial progress. The stock’s valuation premium requires execution on clinical milestones to justify current levels. Ris…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.